PTEN and triple-negative breast carcinoma: Additionally, exploratory biomarker analyses in the neoadjuvant triple-negative breast cancer setting showed that high levels of phosphorylated AKT1 in the absence of PIK3CA/AKT/PTEN alterations were associated with other pathway activation mechanisms, including deficiency of PTEN protein expression and enhanced activation of upstream receptor tyrosine kinases33.